Research Article
BibTex RIS Cite

Koenzim Q10’un ratlarda sıçanlarda sisplatinin neden olduğu ototoksisiteye etkisi

Year 2016, Volume: 6 Issue: 3, 110 - 115, 31.12.2016

Abstract

Objective: To determine the efficacy of systemic administration of coenzyme Q10 at low and high doses on cisplatin-induced ototoxicity in rats.
Methods: Our study was performed with 40 Sprague-Dawley rats. They were divided randomly into five groups: Cis, Cis+Q1030, Cis+Q1010, Q10, and control. Cis (n=8) group was administered cisplatin [a single intraperitoneal (i.p.) injection of 14 mg/kg], Cis+Q1030 (n=8) group was administered cisplatin (a single i.p. injection of 14 mg/kg) and
coenzyme Q10 (30 mg/kg/day, i.p.) for 3 days, Cis+Q1010 (n=8) group was given cisplatin (a single dose of 14 mg/kg/day, i.p.) and coenzyme Q10 (10 mg/kg/day, i.p.) for 3 days, Q10 (n=8) group was administered coenzyme Q10 (10 mg/kg/day, i.p.) for 3 days and Group C (n=8) (control group) was administered saline solution (1 mL/day, i.p.) once daily for 3 days. Pretreatment and posttreatment hearing levels were evaluated with distortion product otoacoustic emissions (DPOAEs).
Results: There was no statistically significant difference in the results of measurements of 4004, 4358, 4761 and 5188 Hz at end of the study in comparison to baseline (p>0.05). On the other hand, there was a significant
difference at the measurements of 5652, 6165, 7336 and 7996 Hz (p=0.002, p=0.037, p=0.001, p=0.001, respectively). The rate of change at 5652 Hz revealed that Cis group was different from Cis+Q1010, control and Q10 groups (p<0.01); measurements at 6165 Hz revealed that change at Cis group was significantly different from control and Q10 groups (p<0.01, p<0.05). Final measurements of decrease in Cis group at 7336 and 7996 Hz were significantly different from baseline (p<0.05; p<0.01).
Conclusion: The high-dose coenzyme Q10 showed a protective effect on hearing in cisplatin-induced ototoxicity while low-dose coenzyme Q10 protected hearing at low frequencies but did not show protective effect at high frequencies.

References

  • 1. Walker EM Jr, Fazekas-May MA, Bowen WR. Nephrotoxic and ototoxic agents. Clin Lab Med 1990;10:323–54.
  • 2. Ravi R, Somani SM, Rybak LP. Mechanism of cisplatin ototoxicity: antioxidant system. Pharmacol Toxicol 1995;76:386–94.
  • 3. Daldal A, Odabasi O, Serbetcioglu B. The protective effect of intratympanic dexamethasone on cisplatin-induced ototoxicity in guinea pigs. Otolaryngol Head Neck Surg 2007;137:747–52.
  • 4. Rybak LP, Whitworth CA, Mukherjea D, Ramkuvar L. Mechanisms of cisplatin-induced ototoxicity and prevention. Hear Res 2007;226:157–67.
  • 5. Van den Berg JH, Beijnen JH, Balm AJ, Schellens JH. Future opportunities in preventing cisplatin induced ototoxicity. Cancer Treat Rev 2006;32:390–7.
  • 6. Fetoni AR, Sergi B, Ferraresi A, Paludetti G, Troiani D. Protective effects of alpha-tocopherol and tiopronin against cisplatin- induced ototoxicity. Acta Otolaryngol 2004;124:421–6.
  • 7. Ise T, Shimizu T, Lee EL, Inoue H, Kohno K, Okada Y. Roles of volume-sensitive Cl-channel in cisplatin-induced apoptosis in human epidermoid cancer cells. J Membr Biol 2005;205:139–45.
  • 8. Van Ruijven MW, de Groot JC, Klis SF, Smoorenbug GF. The cochlear targets of cisplatin: an electrophysiological and morphological time-sequence study. Hear Res 2005;205:241–8.
  • 9. Sergi B, Fetoni AR, Paludetti G, et al. Protective properties of idebenone in noise-induced hearing loss in the guinea pig. Neuroreport 2006;17:857–61.
  • 10. Papucci L, Schiavone N, Witort E, et al. Coenzyme Q10 prevents apoptosis by inhibiting mitochondrial depolarization independently of its free radical scavenging property. J Biol Chem 2003;278: 28220–8.
  • 11. Hinojosa R, Riggs LC, Strauss M, Matz GJ. Temporal bone histopathology of cisplatin ototoxicity. Am J Otol 1995;16:731–40.
  • 12. Hyppolito MA, de Oliveira JA, Rossato M. Cisplatin ototoxicity and otoprotection with sodium salicylate. Eur Arch Otorhinolaryngol 2006;263:798–803.
  • 13. Church MW, Blakley BW, Burgio DL, Gupta AK. WR-2721 (Amifostine) ameliorates cisplatin-induced hearing loss but causes neurotoxicity in hamsters: dose-dependent effects. J Assoc Res Otolaryngol 2004;5:227–37.
  • 14. Korver KD, Rybak LP, Whitworth C, Campbell KM. Round window application of D-methionine provides complete cisplatin otoprotection. Otolaryngol Head Neck Surg 2002;126:683–9.
  • 15. Kalkanis JG, Whitworth C, Rybak LP. Vitamin E reduces cisplatin ototoxicity. Laryngoscope 2004;114:538–42.
  • 16. Berkiten G, Salturk Z, Topalo¤lu I, U¤rafl H. Protective effect of pentoxifylline on amikacin-induced ototoxicity in rats. Am J Otolaryngol 2012;33:689–92.
  • 17. Chen X, Frisina RD, Bowers WJ, Frisina DR, Federoff HJ. HSV amplicon-mediated neurotrophin-3 expression protects murine spiral ganglion neurons from cisplatin-induced damage. Mol Ther 2001;3:958–63.
  • 18. So HS, Park C, Kim HJ, et al. Protective effect of T-type calcium channel blocker flunarizine on cisplatin-induced death of auditory cells. Hear Res 2005;204:127–39.
  • 19. Lopez-Gonzalez MA, Guerrero JM, Rojas F, Delgado F. Ototoxicity caused by cisplatin is ameliorated by melatonin and other antioxidants. J Pineal Res 2000;28:73–80.
  • 20. Rybak LP, Husain K, Morris C, Whitworth C, Somani S. Effect of protective agents against cisplatin ototoxicity. Am J Otol 2000; 21:513–20.
  • 21. Ahn JH, Yoo MH, Lee HJ, Chung JW, Yoon TH. Coenzyme Q10 in combination with steroid therapy for treatment of sudden sensorineural hearing loss: a controlled prospective study. Clin Otolaryngol 2010;35:486–9.
  • 22. Hirose Y, Sugahara K, Mikuriya T, Hashimoto M, Shimogori H, Yamashita H. Effect of water-soluble coenzyme Q10 on noiseinduced hearing loss in guinea pigs. Acta Otolaryngol 2008;128:1071–6.
  • 23. Guastini L, Mora R, Dellepiane M, Santamauro V, Giorgio M, Salami A. Water-soluble coenzyme Q10 formulation in presbycusis: long-term effects. Acta Otolaryngol 2011;131:512–7.
  • 24. Fetoni AR, Eramo SL, Rolesi R, Troiani D, Paludetti G. Antioxidant treatment with coenzyme Q-ter in prevention of gentamycin ototoxicity in an animal model. Acta Otorhinolaryngol Ital 2012;32:103–10.
  • 25. Sockalingam R, Freeman S, Cherny TL, Sohmer T. Effect of high-dose cisplatin on auditory brainstem responses and otoacoustic emissions in laboratory animals. Am J Otol 2000;21:521–7.
  • 26. Fetoni AR, Garzaro M, Ralli M, et al. The monitoring role of otoacoustic emissions and oxidative stress markers in the protective effects of antioxidant administration in noise-exposed subjects: a pilot study. Med Sci Monit 2009;15:PR1–8.
Year 2016, Volume: 6 Issue: 3, 110 - 115, 31.12.2016

Abstract

References

  • 1. Walker EM Jr, Fazekas-May MA, Bowen WR. Nephrotoxic and ototoxic agents. Clin Lab Med 1990;10:323–54.
  • 2. Ravi R, Somani SM, Rybak LP. Mechanism of cisplatin ototoxicity: antioxidant system. Pharmacol Toxicol 1995;76:386–94.
  • 3. Daldal A, Odabasi O, Serbetcioglu B. The protective effect of intratympanic dexamethasone on cisplatin-induced ototoxicity in guinea pigs. Otolaryngol Head Neck Surg 2007;137:747–52.
  • 4. Rybak LP, Whitworth CA, Mukherjea D, Ramkuvar L. Mechanisms of cisplatin-induced ototoxicity and prevention. Hear Res 2007;226:157–67.
  • 5. Van den Berg JH, Beijnen JH, Balm AJ, Schellens JH. Future opportunities in preventing cisplatin induced ototoxicity. Cancer Treat Rev 2006;32:390–7.
  • 6. Fetoni AR, Sergi B, Ferraresi A, Paludetti G, Troiani D. Protective effects of alpha-tocopherol and tiopronin against cisplatin- induced ototoxicity. Acta Otolaryngol 2004;124:421–6.
  • 7. Ise T, Shimizu T, Lee EL, Inoue H, Kohno K, Okada Y. Roles of volume-sensitive Cl-channel in cisplatin-induced apoptosis in human epidermoid cancer cells. J Membr Biol 2005;205:139–45.
  • 8. Van Ruijven MW, de Groot JC, Klis SF, Smoorenbug GF. The cochlear targets of cisplatin: an electrophysiological and morphological time-sequence study. Hear Res 2005;205:241–8.
  • 9. Sergi B, Fetoni AR, Paludetti G, et al. Protective properties of idebenone in noise-induced hearing loss in the guinea pig. Neuroreport 2006;17:857–61.
  • 10. Papucci L, Schiavone N, Witort E, et al. Coenzyme Q10 prevents apoptosis by inhibiting mitochondrial depolarization independently of its free radical scavenging property. J Biol Chem 2003;278: 28220–8.
  • 11. Hinojosa R, Riggs LC, Strauss M, Matz GJ. Temporal bone histopathology of cisplatin ototoxicity. Am J Otol 1995;16:731–40.
  • 12. Hyppolito MA, de Oliveira JA, Rossato M. Cisplatin ototoxicity and otoprotection with sodium salicylate. Eur Arch Otorhinolaryngol 2006;263:798–803.
  • 13. Church MW, Blakley BW, Burgio DL, Gupta AK. WR-2721 (Amifostine) ameliorates cisplatin-induced hearing loss but causes neurotoxicity in hamsters: dose-dependent effects. J Assoc Res Otolaryngol 2004;5:227–37.
  • 14. Korver KD, Rybak LP, Whitworth C, Campbell KM. Round window application of D-methionine provides complete cisplatin otoprotection. Otolaryngol Head Neck Surg 2002;126:683–9.
  • 15. Kalkanis JG, Whitworth C, Rybak LP. Vitamin E reduces cisplatin ototoxicity. Laryngoscope 2004;114:538–42.
  • 16. Berkiten G, Salturk Z, Topalo¤lu I, U¤rafl H. Protective effect of pentoxifylline on amikacin-induced ototoxicity in rats. Am J Otolaryngol 2012;33:689–92.
  • 17. Chen X, Frisina RD, Bowers WJ, Frisina DR, Federoff HJ. HSV amplicon-mediated neurotrophin-3 expression protects murine spiral ganglion neurons from cisplatin-induced damage. Mol Ther 2001;3:958–63.
  • 18. So HS, Park C, Kim HJ, et al. Protective effect of T-type calcium channel blocker flunarizine on cisplatin-induced death of auditory cells. Hear Res 2005;204:127–39.
  • 19. Lopez-Gonzalez MA, Guerrero JM, Rojas F, Delgado F. Ototoxicity caused by cisplatin is ameliorated by melatonin and other antioxidants. J Pineal Res 2000;28:73–80.
  • 20. Rybak LP, Husain K, Morris C, Whitworth C, Somani S. Effect of protective agents against cisplatin ototoxicity. Am J Otol 2000; 21:513–20.
  • 21. Ahn JH, Yoo MH, Lee HJ, Chung JW, Yoon TH. Coenzyme Q10 in combination with steroid therapy for treatment of sudden sensorineural hearing loss: a controlled prospective study. Clin Otolaryngol 2010;35:486–9.
  • 22. Hirose Y, Sugahara K, Mikuriya T, Hashimoto M, Shimogori H, Yamashita H. Effect of water-soluble coenzyme Q10 on noiseinduced hearing loss in guinea pigs. Acta Otolaryngol 2008;128:1071–6.
  • 23. Guastini L, Mora R, Dellepiane M, Santamauro V, Giorgio M, Salami A. Water-soluble coenzyme Q10 formulation in presbycusis: long-term effects. Acta Otolaryngol 2011;131:512–7.
  • 24. Fetoni AR, Eramo SL, Rolesi R, Troiani D, Paludetti G. Antioxidant treatment with coenzyme Q-ter in prevention of gentamycin ototoxicity in an animal model. Acta Otorhinolaryngol Ital 2012;32:103–10.
  • 25. Sockalingam R, Freeman S, Cherny TL, Sohmer T. Effect of high-dose cisplatin on auditory brainstem responses and otoacoustic emissions in laboratory animals. Am J Otol 2000;21:521–7.
  • 26. Fetoni AR, Garzaro M, Ralli M, et al. The monitoring role of otoacoustic emissions and oxidative stress markers in the protective effects of antioxidant administration in noise-exposed subjects: a pilot study. Med Sci Monit 2009;15:PR1–8.
There are 26 citations in total.

Details

Subjects Health Care Administration
Journal Section Articles
Authors

Güler Berkiten This is me

Tolgar Lütfi Kumral This is me

Ziya Saltürk This is me

Belgin Tutar This is me

Ayşe Enise Göker This is me

Gürcan Sünnetçi This is me

Yavuz Uyar This is me

Hilmi Uğraş This is me

Publication Date December 31, 2016
Submission Date July 24, 2017
Published in Issue Year 2016 Volume: 6 Issue: 3

Cite

APA Berkiten, G., Kumral, T. L., Saltürk, Z., Tutar, B., et al. (2016). Koenzim Q10’un ratlarda sıçanlarda sisplatinin neden olduğu ototoksisiteye etkisi. ENT Updates, 6(3), 110-115.
AMA Berkiten G, Kumral TL, Saltürk Z, Tutar B, Göker AE, Sünnetçi G, Uyar Y, Uğraş H. Koenzim Q10’un ratlarda sıçanlarda sisplatinin neden olduğu ototoksisiteye etkisi. ENT Updates. December 2016;6(3):110-115.
Chicago Berkiten, Güler, Tolgar Lütfi Kumral, Ziya Saltürk, Belgin Tutar, Ayşe Enise Göker, Gürcan Sünnetçi, Yavuz Uyar, and Hilmi Uğraş. “Koenzim Q10’un Ratlarda sıçanlarda Sisplatinin Neden olduğu Ototoksisiteye Etkisi”. ENT Updates 6, no. 3 (December 2016): 110-15.
EndNote Berkiten G, Kumral TL, Saltürk Z, Tutar B, Göker AE, Sünnetçi G, Uyar Y, Uğraş H (December 1, 2016) Koenzim Q10’un ratlarda sıçanlarda sisplatinin neden olduğu ototoksisiteye etkisi. ENT Updates 6 3 110–115.
IEEE G. Berkiten, T. L. Kumral, Z. Saltürk, B. Tutar, A. E. Göker, G. Sünnetçi, Y. Uyar, and H. Uğraş, “Koenzim Q10’un ratlarda sıçanlarda sisplatinin neden olduğu ototoksisiteye etkisi”, ENT Updates, vol. 6, no. 3, pp. 110–115, 2016.
ISNAD Berkiten, Güler et al. “Koenzim Q10’un Ratlarda sıçanlarda Sisplatinin Neden olduğu Ototoksisiteye Etkisi”. ENT Updates 6/3 (December 2016), 110-115.
JAMA Berkiten G, Kumral TL, Saltürk Z, Tutar B, Göker AE, Sünnetçi G, Uyar Y, Uğraş H. Koenzim Q10’un ratlarda sıçanlarda sisplatinin neden olduğu ototoksisiteye etkisi. ENT Updates. 2016;6:110–115.
MLA Berkiten, Güler et al. “Koenzim Q10’un Ratlarda sıçanlarda Sisplatinin Neden olduğu Ototoksisiteye Etkisi”. ENT Updates, vol. 6, no. 3, 2016, pp. 110-5.
Vancouver Berkiten G, Kumral TL, Saltürk Z, Tutar B, Göker AE, Sünnetçi G, Uyar Y, Uğraş H. Koenzim Q10’un ratlarda sıçanlarda sisplatinin neden olduğu ototoksisiteye etkisi. ENT Updates. 2016;6(3):110-5.